NCT00567840View on ClinicalTrials.gov

PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

PA-824

200 mg, 600 mg, 100 mg, 1200 mg qd

Trial Locations (2)

8000

Tiervlei Trials Center, Stellenbosch University, Cape Town

Unknown

University of Cape Town Lung Institute, Cape Town

All Listed Sponsors
lead

Global Alliance for TB Drug Development

OTHER

NCT00567840 - PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter